280 related articles for article (PubMed ID: 27028808)
21. Functions of Shp2 in cancer.
Zhang J; Zhang F; Niu R
J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
[TBL] [Abstract][Full Text] [Related]
22. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
23. The Noonan syndrome-associated D61G variant of the protein tyrosine phosphatase SHP2 prevents synaptic down-scaling.
Lu W; Ai H; Xue F; Luan Y; Zhang B
J Biol Chem; 2020 Jul; 295(29):10023-10031. PubMed ID: 32499374
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
25. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
26. The role of Shp2 (PTPN11) in cancer.
Mohi MG; Neel BG
Curr Opin Genet Dev; 2007 Feb; 17(1):23-30. PubMed ID: 17227708
[TBL] [Abstract][Full Text] [Related]
27. The tyrosine phosphatase Shp2 in development and cancer.
Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
[TBL] [Abstract][Full Text] [Related]
28. The role of the protein tyrosine phosphatase SHP2 in ossification.
Zhang Y; Lu W; Zhao Q; Chen J; Wang T; Ji J
Dev Dyn; 2022 May; 251(5):748-758. PubMed ID: 34962674
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
30. Phosphoproteomics-mediated identification of Fer kinase as a target of mutant Shp2 in Noonan and LEOPARD syndrome.
Paardekooper Overman J; Preisinger C; Prummel K; Bonetti M; Giansanti P; Heck A; den Hertog J
PLoS One; 2014; 9(9):e106682. PubMed ID: 25184253
[TBL] [Abstract][Full Text] [Related]
31. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
[TBL] [Abstract][Full Text] [Related]
32. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
[TBL] [Abstract][Full Text] [Related]
33. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
[TBL] [Abstract][Full Text] [Related]
34. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
[TBL] [Abstract][Full Text] [Related]
35. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
36. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Song Y; Zhao M; Zhang H; Yu B
Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
[TBL] [Abstract][Full Text] [Related]
37. Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions.
Bellio M; Garcia C; Edouard T; Voisin S; Neel BG; Cabou C; Valet P; Mori J; Mazharian A; Senis YA; Yart A; Payrastre B; Severin S
Blood; 2019 Dec; 134(25):2304-2317. PubMed ID: 31562133
[TBL] [Abstract][Full Text] [Related]
38. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
Yi JS; Perla S; Enyenihi L; Bennett AM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
[TBL] [Abstract][Full Text] [Related]
39. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
Stewart RA; Sanda T; Widlund HR; Zhu S; Swanson KD; Hurley AD; Bentires-Alj M; Fisher DE; Kontaridis MI; Look AT; Neel BG
Dev Cell; 2010 May; 18(5):750-62. PubMed ID: 20493809
[TBL] [Abstract][Full Text] [Related]
40. Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
